ChemRar Group took part in the Russia-Africa Summit 2023
During the period from July 27 to 28, the Economic and Humanitarian Forum took place in St. Petersburg as part of the Second Russia-Africa Summit. ChemRar Group, led by Irina Yuryevna Tyrnova, a member of the board of directors and head of export development, took part in the business program of the forum.
As part of the Forum, a working meeting was held between the head of state of Burkina Faso, Captain Ibrahim Traoré, and a delegation of the BRICS Alliance, which included representatives of the ChemRar Group. The President of the BRICS Alliance, Larisa Zelentsova, announced her intention to build a medical center in Burkina Faso, as well as a drug production plant. Earlier, the Government of Burkina Faso and the BRICS International Alliance signed a memorandum of cooperation. During the meeting, the possibility of supplying 50,000 packages of the drug “AVIFAVIR”, the world’s first registered direct antiviral drug for the treatment of COVID-19, developed and produced by scientists of the ChemRar Group, was also discussed as part of humanitarian aid, with subsequent registration and supply medicines from ChemRar Group to Burkina Faso on a permanent basis. The prospect of partial localization of drug production on the territory of an African state was also discussed. “President Traore promised full support of the executive authorities in the implementation of our projects,” commented the representative of the ChemRar Group of Companies Sergei Restevanyan on the meeting.
President of Burkina Faso Ibrahim Traore at a working meeting with representatives of the BRICS alliance
At the exhibition of Forum in the «Pharmaceutics and Medicine» cluster, ChemRar Group presented an updated portfolio of drugs for the treatment of oncological, viral, neurological, autoimmune and orphan diseases, including both innovative and import-substituting drugs, which are produced in a full cycle in Russia. Director for Business Development and Communications of ChemRar Group Denis Vinokurov made a presentation of the exported portfolio of drugs of the group of companies, in particular those already registered and supplied to different countries of the world.
Director for Business Development and Communications of ChemRar Group of Companies Denis Vinokurov at the presentation of the exported portfolio of drugs of the group of companies
The Minister of Health of the Russian Federation, Mikhail Murashko, toured the cluster and introduced Russian companies to his colleagues from African countries. Murashko announced the Russian Federation’s readiness to supply drugs for the treatment of HIV infection to Africa: “It is necessary to note a wide range of drugs to combat viral infections, including, among other things, the human immunodeficiency virus. Moreover, I would like to note that according to the Federal Antimonopoly Service, prices for this group of drugs are the lowest in the world, which, in general, ensures their availability for our patients in the Russian Federation,” the Minister said at a session of the Russia-Africa summit. According to information for 2022, about 25.6 million people living with diagnosed HIV live in Africa, 660,000 new cases were diagnosed during the year. In a number of countries, the proportion of the HIV-infected population reaches ¼ from general numbers . ChemRar Group expressed readiness turn on V given direction cooperation between states V fight With HIV .
ChemRar Group develops and produces a number of products in this area, in particular, the first innovative drug ELPIDA® in the 21st century for the treatment of HIV infection, which today is the best in its class (NNRTI), quickly reducing the viral load in the blood and while having fewer side effects compared to other drugs on the market. In addition, a fixed-dose combination of tenofovir entered the market at the end of 2022 disoproxil fumarate , elsulfavirin and emtricitabine – ELPIDA® COMBI. Simplification of the dosage regimen and improvement of patient adherence to therapy when using a combination drug is one of the most important properties of ELPIDA® COMBI.
Currently, Elpida LLC of the ChemRar Group, with the support of the Skolkovo Foundation, is researching and developing the injectable intramuscular nanoformulation VM-1500A-LAI, a prolonged form of the active metabolite of elsulfavirine . Thanks to the innovative formula of the drug, it will be enough to use it at least once a month or less often.
Representatives of the ChemRar Group at the Economic and Humanitarian Forum within the framework of the Second Russia-Africa Summit
Separately, meetings were held between representatives of the ChemRar Group with high-ranking official representatives of a number of states, as well as business representatives from such African countries as: Algeria, Angola, Guinea, Egypt, Zambia, Zimbabwe, Cameroon, Kenya, Congo, Cote d’Ivoire, Mauritius , Mali, Nigeria, Somalia, Tanzania, Togo, Chad, South Sudan. Representatives of African states expressed interest in the products of the ChemRar Group, as a result of which possible cooperation was discussed both on commercial supplies and technology transfer, and on scientific cooperation in the development of new drugs.
“The work being carried out in Africa has only recently begun, but we are already looking at areas of cooperation where there is significant potential and where we can be useful with our competencies and products for patients in African countries. As the forum shows, there are a large number of partners working in this region in the field of pharmaceuticals, many of whom have shown great interest and desire to cooperate with Russian companies,” said Irina Tyrnova, member of the board of directors and head of export development.
Member of the Board of Directors and head of export development Irina Tyrnova at the Economic and Humanitarian Forum within the framework of the Second Russia-Africa Summit